A randomized, double-blind, placebo controlled trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of lixisenatide in paediatric (10 - 17 years old) and adult patients with type 2 diabetes.
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2016
At a glance
- Drugs Lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 22 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Oct 2013 Planned end date changed from 1 Dec 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 03 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.